Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Radium-223 dichloride (radium-223), an alpha emitter, selectively targets bone metastases with alpha particles. We assessed the efficacy and safety of radium-223 as compared with placebo, in addition to the best standard of care, in men with castration-resistant prostate cancer and bone metastases. METHODS: In our phase 3, randomized, double-blind, placebo-controlled study, we randomly assigned 921 patients who had received, were not eligible to receive, or declined docetaxel, in a 2:1 ratio, to receive six injections of radium-223 (at a dose of 50 kBq per kilogram of body weight intravenously) or matching placebo; one injection was administered every 4 weeks. In addition, all patients received the best standard of care. The primary end point was overall survival. The main secondary efficacy end points included time to the first symptomatic skeletal event and various biochemical end points. A prespecified interim analysis, conducted when 314 deaths had occurred, assessed the effect of radium-223 versus placebo on survival. An updated analysis, when 528 deaths had occurred, was performed before crossover from placebo to radium-223. RESULTS: At the interim analysis, which involved 809 patients, radium-223, as compared with placebo, significantly improved overall survival (median, 14.0 months vs. 11.2 months; hazard ratio, 0.70; 95% confidence interval [CI], 0.55 to 0.88; two-sided P=0.002). The updated analysis involving 921 patients confirmed the radium-223 survival benefit (median, 14.9 months vs. 11.3 months; hazard ratio, 0.70; 95% CI, 0.58 to 0.83; P<0.001). Assessments of all main secondary efficacy end points also showed a benefit of radium-233 as compared with placebo. Radium-223 was associated with low myelosuppression rates and fewer adverse events. CONCLUSIONS: In this study, which was terminated for efficacy at the prespecified interim analysis, radium-223 improved overall survival. (Funded by Algeta and Bayer HealthCare Pharmaceuticals; ALSYMPCA ClinicalTrials.gov number, NCT00699751.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“R adiopharmaceutical therapies are gaining increasing prominence as they improve survival in patients with common diseases such as metastatic prostate cancer ( 1 , 2 ).”
From Normal-Tissue Tolerance to Radiopharmaceutical Therapies, the Knowns and the Unknowns (2021) · cites this paper as [2]
In the citing paper
“Although improvements in clinical outcomes have been observed with novel therapies [20–31], their approval has resulted in uncertainties on optimal treatment sequencing, and utilization of these treatments is limited, demonstrating the need for improved real-world treatment practices.”
From Navigating therapeutic sequencing in the metastatic castration-resistant prostate cancer patient journey (2025) · cites this paper as [23]
In the citing paper
“These are particularly substantial in the post-ARPI space, as pivotal trials of many current treatments were performed in patients who had not received a prior ARPI [22, 23, 30, 92].”
From Navigating therapeutic sequencing in the metastatic castration-resistant prostate cancer patient journey (2025) · cites this paper as [23]
In the citing paper
“Additionally, pivotal trials of current treatments utilized conventional imaging to determine metastatic disease [22, 23, 30, 92].”
From Navigating therapeutic sequencing in the metastatic castration-resistant prostate cancer patient journey (2025) · cites this paper as [23]
In the citing paper
“Best standard non- | ALSYMPCA Castration refractory | OS | | | 11.3 months 3.6 months | 0.70 (0.55-0.88) Improved | 5 | [68]”
Citations
Cites
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., McFadden, E. T., & Carbone, P. P. (1982) · AMERICAN JOURNAL OF CLINICAL ONCOLOGY · doi:10.1097/00000421-198212000-00014 · Cited by 11,647
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., Oudard, S., Théodore, C., James, N. D., Turesson, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040720 · Cited by 5,735 · cited 5×
“Asthenia 35 (6) 5 (1) 0 0 18 (6) 4 (1) 0 0”
InfluentialSelf-citationIncreased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Scher, H. I., Fizazi, K., Saad, F., Taplin, M.-E., Sternberg, C. N., Miller, K., de Wit, R., Mulders, P., Chi, K. N., Shore, N. D., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1207506 · Cited by 4,586
Abiraterone and Increased Survival in Metastatic Prostate Cancer
de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K. N., Jones, R. J., Goodman, O. B., Saad, F., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014618 · Cited by 4,407
de Bono, J. S., Oudard, S., Ozguroglu, M., Hansen, S., Machiels, J.-P., Kocak, I., Gravis, G., Bodrogi, I., Mackenzie, M. J., Shen, L., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61389-x · Cited by 3,318
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
Roodman, G. D. (2004) · New England Journal of Medicine · doi:10.1056/nejmra030831 · Cited by 2,755
Discrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310
Discrete Sequential Boundaries for Clinical Trials
Lan, K. K. G., & DeMets, D. L. (1983) · Biometrika · doi:10.2307/2336502 · Cited by 2,310
Fizazi, K., Carducci, M., Smith, M., Damião, R., Brown, J., Karsh, L., Milecki, P., Shore, N., Rader, M., Wang, H., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62344-6 · Cited by 1,971
Research works printed but not linked: 4
- Lewington VJ, 2005, J Nucl Med, 46, 38S
- Henriksen G, 2002, Cancer Res, 62, 3120
- Henriksen G, 2003, J Nucl Med, 44, 252
- Liepe K, 2009, Curr Opin Investig Drugs, 10, 1346
Cited by
Items 101–200 of 1,005
Fendler, W. P., Reinhardt, S., Ilhan, H., Delker, A., Böning, G., Gildehaus, F. J., Stief, C., Bartenstein, P., Gratzke, C., Lehner, S., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.12240 · Cited by 223
A Review of Theranostics: Perspectives on Emerging Approaches and Clinical Advancements
Burkett, B. J., Bartlett, D. J., McGarrah, P. W., Lewis, A. R., Johnson, D. R., Berberoğlu, K., Pandey, M. K., Packard, A. T., Halfdanarson, T. R., Hruska, C. B., et al. (2023) · Radiology: Imaging Cancer · doi:10.1148/rycan.220157 · Cited by 217
Roles of Matrix Metalloproteinases and Their Natural Inhibitors in Prostate Cancer Progression
Gong, Y., Chippada-Venkata, U., & Oh, W. (2014) · Cancers · doi:10.3390/cancers6031298 · Cited by 211
Sathekge, M. M., Lawal, I. O., Bal, C., Bruchertseifer, F., Ballal, S., Cardaci, G., Davis, C., Eiber, M., Hekimsoy, T., Knoesen, O., et al. (2024) · The Lancet Oncology · doi:10.1016/s1470-2045(23)00638-1 · Cited by 210
Castration-Resistant Prostate Cancer: AUA Guideline Amendment
Cookson, M. S., Lowrance, W. T., Murad, M. H., & Kibel, A. S. (2015) · Journal of Urology · doi:10.1016/j.juro.2014.10.104 · Cited by 209
Future cancer research priorities in the USA: a Lancet Oncology Commission
Jaffee, E. M., Dang, C. V., Agus, D. B., Alexander, B. M., Anderson, K. C., Ashworth, A., Barker, A. D., Bastani, R., Bhatia, S., Bluestone, J. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30698-8 · Cited by 208
Novel approaches to target the microenvironment of bone metastasis
Hofbauer, L. C., Bozec, A., Rauner, M., Jakob, F., Perner, S., & Pantel, K. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00499-9 · Cited by 207
177Lu-PSMA Radioligand Therapy for Prostate Cancer
Fendler, W. P., Rahbar, K., Herrmann, K., Kratochwil, C., & Eiber, M. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.191023 · Cited by 206
“Rates for serious hematologic adverse events after 177Lu-PSMA (3%–10%) were similar to those reported for mCRPC patients treated with placebo (1%–14%) or 223Ra (3%– 13%) within the ALSYMPCA trial (42).”
Treatment of Advanced Prostate Cancer—A Review of Current Therapies and Future Promise
Sumanasuriya, S., & De Bono, J. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a030635 · Cited by 203
“Radium is given as four weekly intravenous infusions for a total of six cycles (Parker et al. 2013), although the optimal dose, schedule, and duration of treatment with this agent is not yet well defined.”
BackgroundOverview of the Most Promising Radionuclides for Targeted Alpha Therapy: The “Hopeful Eight”
Eychenne, R., Chérel, M., Haddad, F., Guérard, F., & Gestin, J.-F. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13060906 · Cited by 196
“Finally, it confirmed the interest in 223Ra treatment and also opened new prospects for a possible association with chemotherapy agent [255,256].”
BackgroundFizazi, K., Massard, C., Bono, P., Jones, R., Kataja, V., James, N., Garcia, J. A., Protheroe, A., Tammela, T. L., Elliott, T., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70240-2 · Cited by 196
Self-citationJambor, I., Kuisma, A., Ramadan, S., Huovinen, R., Sandell, M., Kajander, S., Kemppainen, J., Kauppila, E., Auren, J., Merisaari, H., et al. (2016) · Acta Oncologica · doi:10.3109/0284186x.2015.1027411 · Cited by 198
Sathekge, M., Bruchertseifer, F., Vorster, M., Lawal, I. O., Knoesen, O., Mahapane, J., Davis, C., Reyneke, F., Maes, A., Kratochwil, C., et al. (2020) · Journal of Nuclear Medicine · doi:10.2967/jnumed.119.229229 · Cited by 193
“223Ra-dichloride is an approved a-emitting radionuclide with survival benefit in patients with predominantly bone metastases of prostate cancer (6).”
BackgroundThe Potential and Hurdles of Targeted Alpha Therapy – Clinical Trials and Beyond
Elgqvist, J., Frost, S., Pouget, J.-P., & Albertsson, P. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2013.00324 · Cited by 194
“injected 223Ra-dicloride (Xofigo®, formerly named Alpharadin) in a placebo-controlled phase III trial for castration-resistant prostate cancer metastases (20).”
BackgroundInfluentialKulkarni, H. R., Singh, A., Schuchardt, C., Niepsch, K., Sayeg, M., Leshch, Y., Wester, H.-J., & Baum, R. P. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.170167 · Cited by 192
Loriot, Y., Miller, K., Sternberg, C. N., Fizazi, K., De Bono, J. S., Chowdhury, S., Higano, C. S., Noonberg, S., Holmstrom, S., Mansbach, H., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70113-0 · Cited by 191
Gomes Marin, J. F., Nunes, R. F., Coutinho, A. M., Zaniboni, E. C., Costa, L. B., Barbosa, F. G., Queiroz, M. A., Cerri, G. G., & Buchpiguel, C. A. (2020) · RadioGraphics · doi:10.1148/rg.2020200021 · Cited by 190
Targeted alpha therapy: progress in radionuclide production, radiochemistry, and applications.
Nelson, B. J. B., Andersson, J. D., & Wuest, F. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics13010049 · Cited by 194
Crawford, E. D., Higano, C. S., Shore, N. D., Hussain, M., & Petrylak, D. P. (2015) · Journal of Urology · doi:10.1016/j.juro.2015.06.106 · Cited by 190
Lolli, C., Caffo, O., Scarpi, E., Aieta, M., Conteduca, V., Maines, F., Bianchi, E., Massari, F., Veccia, A., Chiuri, V. E., et al. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00376 · Cited by 188
Rahbar, K., Bode, A., Weckesser, M., Avramovic, N., Claesener, M., Stegger, L., & Bögemann, M. (2016) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000001240 · Cited by 187
Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study
Nilsson, S., Cislo, P., Sartor, O., Vogelzang, N. J., Coleman, R. E., O'Sullivan, J. M., Reuning-Scherer, J., Shan, M., Zhan, L., & Parker, C. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw065 · Cited by 182
Self-citationYadav, M. P., Ballal, S., Sahoo, R. K., Dwivedi, S. N., & Bal, C. (2019) · American Journal of Roentgenology · doi:10.2214/ajr.18.20845 · Cited by 182
Thang, S. P., Violet, J., Sandhu, S., Iravani, A., Akhurst, T., Kong, G., Ravi Kumar, A., Murphy, D. G., Williams, S. G., Hicks, R. J., et al. (2019) · European Urology Oncology · doi:10.1016/j.euo.2018.11.007 · Cited by 183
George, D. J., Sartor, O., Miller, K., Saad, F., Tombal, B., Kalinovský, J., Jiao, X., Tangirala, K., Sternberg, C. N., & Higano, C. S. (2020) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2019.12.019 · Cited by 179
Self-citationSuominen, M. I., Fagerlund, K. M., Rissanen, J. P., Konkol, Y. M., Morko, J. P., Peng, Z., Alhoniemi, E. J., Laine, S. K., Corey, E., Mumberg, D., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2955 · Cited by 177
“Although currently used palliative therapies for bone metastases in CRPC, such as zoledronic acid and the RANK-L inhibitor denosumab, are capable of reducing SREs and provide pain palliation (22–25), the targeted alpha therapy radium-223 is the first drug with proven beneficial effect on overall survival (10).”
BackgroundBräuer, A., Grubert, L. S., Roll, W., Schrader, A. J., Schäfers, M., Bögemann, M., & Rahbar, K. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3751-z · Cited by 173
“Only ALP level 220 U/L was significantly associated with a longer PPFS (41 vs. 18 weeks, p 0.01).”
MethodInfluentialThe Biology of Bone Metastasis
Esposito, M., Guise, T., & Kang, Y. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a031252 · Cited by 170
“This agent targets bone-forming activity and has been shown to improve overall survival in prostate cancer patients with bone metastases (Parker et al. 2013; Hoskin et al. 2014; Sartor et al. 2014).”
Ahmadzadehfar, H., Wegen, S., Yordanova, A., Fimmers, R., Kürpig, S., Eppard, E., Wei, X., Schlenkhoff, C., Hauser, S., & Essler, M. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3716-2 · Cited by 170
Bone Metastasis of Breast Cancer
Tahara, R. K., Brewer, T. M., Theriault, R. L., & Ueno, N. T. (2019) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-030-20301-6_7 · Cited by 169
Dekempeneer, Y., Keyaerts, M., Krasniqi, A., Puttemans, J., Muyldermans, S., Lahoutte, T., D’huyvetter, M., & Devoogdt, N. (2016) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2016.1185412 · Cited by 171
Chi, K. N., Kheoh, T., Ryan, C. J., Molina, A., Bellmunt, J., Vogelzang, N. J., Rathkopf, D. E., Fizazi, K., Kantoff, P. W., Li, J., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdv594 · Cited by 167
Self-citationHalabi, S., Lin, C.-Y., Small, E. J., Armstrong, A. J., Kaplan, E. B., Petrylak, D., Sternberg, C. N., Shen, L., Oudard, S., de Bono, J., et al. (2013) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt280 · Cited by 165
Self-citationSartor, O., Coleman, R. E., Nilsson, S., Heinrich, D., Helle, S. I., O’Sullivan, J. M., Vogelzang, N. J., Bruland, Ø., Kobina, S., Wilhelm, S., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx044 · Cited by 166
“In ALSYMPCA, radium-223 treatment prolonged survival for patients with CRPC and bone-only metastases [18].”
BackgroundInfluentialSelf-citationMetastatic prostate cancer remains incurable, why?
Dong, L., Zieren, R. C., Xue, W., de Reijke, T. M., & Pienta, K. J. (2019) · Asian Journal of Urology · doi:10.1016/j.ajur.2018.11.005 · Cited by 164
Hofman, M. S., Emmett, L., Violet, J., Y. Zhang, A., Lawrence, N. J., Stockler, M., Francis, R. J., Iravani, A., Williams, S., Azad, A., et al. (2019) · BJU International · doi:10.1111/bju.14876 · Cited by 165
Al Nakouzi, N., Le Moulec, S., Albigès, L., Wang, C., Beuzeboc, P., Gross-Goupil, M., de La Motte Rouge, T., Guillot, A., Gajda, D., Massard, C., et al. (2015) · European Urology · doi:10.1016/j.eururo.2014.04.015 · Cited by 164
Aggarwal, A., Fojo, T., Chamberlain, C., Davis, C., & Sullivan, R. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx110 · Cited by 162
“The nine indications that met ESMO criteria for meaningful clinical benefit included, cetuximab for colorectal cancer [23], crizotinib for lung cancer [24], dabrafenib for metastatic melanoma [25], imatinib as adjuvant therapy for GIST [33], pertuzumab and trastuzumab emtansine for breast cancer [44, 51], temsirolimus…”
BackgroundPoeppel, T. D., Handkiewicz-Junak, D., Andreeff, M., Becherer, A., Bockisch, A., Fricke, E., Geworski, L., Heinzel, A., Krause, B. J., Krause, T., et al. (2018) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3900-4 · Cited by 161
Chiesa, C., Mira, M., Maccauro, M., Spreafico, C., Romito, R., Morosi, C., Camerini, T., Carrara, M., Pellizzari, S., Negri, A., et al. (2015) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-015-3068-8 · Cited by 164
Development of targeted alpha particle therapy for solid tumors.
Tafreshi, N. K., Doligalski, M. L., Tichacek, C. J., Pandya, D. N., Budzevich, M. M., El-Haddad, G., Khushalani, N. I., Moros, E. G., McLaughlin, M. L., Wadas, T. J., et al. (2019) · Molecules · doi:10.3390/molecules24234314 · Cited by 157
“In the first-in-human single dosage phase I trial for patients with breast and prostate cancer skeletal metastases, single dose Ra-223 was well tolerated at all therapeutically relevant doses (46–250 kBq/kg intravenously [IV]) [257].”
BackgroundMethodInfluentialDoubly blind: a systematic review of gender in randomised controlled trials
Phillips, S. P., & Hamberg, K. (2016) · Global Health Action · doi:10.3402/gha.v9.29597 · Cited by 155
Current status of theranostics in prostate cancer
Virgolini, I. J., Decristoforo, C., Haug, A. R., Fanti, S., & Uprimny, C. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3882-2 · Cited by 164
Mechanisms of Therapeutic Resistance in Prostate Cancer
Nakazawa, M., Paller, C., & Kyprianou, N. (2017) · Current Oncology Reports · doi:10.1007/s11912-017-0568-7 · Cited by 154
Metastatic Prostate Cancer: Treatment Options
Achard, V., Putora, P. M., Omlin, A. G., Zilli, T., & Fischer, S. (2021) · Oncology · doi:10.1159/000519861 · Cited by 164
Decline in Circulating Tumor Cell Count and Treatment Outcome in Advanced Prostate Cancer
Lorente, D., Olmos, D., Mateo, J., Bianchini, D., Seed, G., Fleisher, M., Danila, D. C., Flohr, P., Crespo, M., Figueiredo, I., et al. (2016) · European Urology · doi:10.1016/j.eururo.2016.05.023 · Cited by 169
Targeting Angiogenesis in Prostate Cancer
Melegh, Z., & Oltean, S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20112676 · Cited by 161
“Radium-223 dichloride is used in symptomatic patients with bone metastases and no known visceral metastases [17].”
BackgroundBerenguer, C. V., Pereira, F., Câmara, J. S., & Pereira, J. A. M. (2023) · Current Oncology · doi:10.3390/curroncol30020178 · Cited by 194
Grubmüller, B., Senn, D., Kramer, G., Baltzer, P., D’Andrea, D., Grubmüller, K. H., Mitterhauser, M., Eidherr, H., Haug, A. R., Wadsak, W., et al. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-4236-4 · Cited by 148
Den, R. B., Feng, F. Y., Showalter, T. N., Mishra, M. V., Trabulsi, E. J., Lallas, C. D., Gomella, L. G., Kelly, W. K., Birbe, R. C., McCue, P. A., et al. (2014) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2014.04.052 · Cited by 148
Sequencing of agents in castration-resistant prostate cancer
Lorente, D., Mateo, J., Pérez-López, R., Bono, J. S. D., & Attard, G. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70033-1 · Cited by 156
Revisiting the Radiobiology of Targeted Alpha Therapy
Pouget, J., & Constanzo, J. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.692436 · Cited by 162
“Another example of bystander effects comes from studies on (223)RaCl2 that has been approved for patients with metastatic castration-resistant prostate cancer or with symptomatic bone metastases after at least two prior lines of systemic therapy (64, 65).”
BackgroundPezaro, C. J., Omlin, A. G., Altavilla, A., Lorente, D., Ferraldeschi, R., Bianchini, D., Dearnaley, D., Parker, C., de Bono, J. S., & Attard, G. (2014) · European Urology · doi:10.1016/j.eururo.2013.11.044 · Cited by 147
Self-citationDosimetry of bone metastases in targeted radionuclide therapy with alpha-emitting 223Ra-dichloride
Pacilio, M., Ventroni, G., Vincentis, G. D., Cassano, B., Pellegrini, R., Castro, E. D., Frantellizzi, V., Follacchio, G. A., Garkavaya, T., Lorenzon, L., et al. (2015) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-015-3150-2 · Cited by 146
Current Overview of Treatment for Metastatic Bone Disease
Tsukamoto, S., Kido, A., Tanaka, Y., Facchini, G., Peta, G., Rossi, G., & Mavrogenis, A. F. (2021) · Current Oncology · doi:10.3390/curroncol28050290 · Cited by 146
Smith, M. R., Coleman, R. E., Klotz, L., Pittman, K., Milecki, P., Ng, S., Chi, K. N., Balakumaran, A., Wei, R., Wang, H., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdu519 · Cited by 145
Self-citationTempleton, A. J., Pezaro, C., Omlin, A., McNamara, M. G., Leibowitz‐Amit, R., Vera‐Badillo, F. E., Attard, G., de Bono, J. S., Tannock, I. F., & Amir, E. (2014) · Cancer · doi:10.1002/cncr.28890 · Cited by 145
Fitzpatrick, J. M., Bellmunt, J., Fizazi, K., Heidenreich, A., Sternberg, C. N., Tombal, B., Alcaraz, A., Bahl, A., Bracarda, S., Di Lorenzo, G., et al. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2014.03.010 · Cited by 145
Self-citationProstate Cancer Biomarkers: From diagnosis to prognosis and precision-guided therapeutics
Adamaki, M., & Zoumpourlis, V. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107932 · Cited by 157
Recent Advances in the Management of Metastatic Prostate Cancer
Sayegh, N., Swami, U., & Agarwal, N. (2022) · JCO Oncology Practice · doi:10.1200/op.21.00206 · Cited by 142
Kakehi, Y., Sugimoto, M., & Taoka, R. (2017) · International Journal of Urology · doi:10.1111/iju.13380 · Cited by 144
Theranostics and artificial intelligence: new frontiers in personalized medicine
Bilgin, G. B., Bilgin, C., Burkett, B. J., Orme, J. J., Childs, D. S., Thorpe, M. P., Halfdanarson, T. R., Johnson, G. B., Kendi, A. T., & Sartor, O. (2024) · Theranostics · doi:10.7150/thno.94788 · Cited by 139
Self-citationAzad, A., Bressel, M., Tan, H., Voskoboynik, M., Suder, A., Weickhardt, A. J., Guminski, A. D., Francis, R. J., Saghebi, J., Dhiantravan, N., et al. (2024) · The Lancet Oncology · doi:10.1016/s1470-2045(24)00440-6 · Cited by 153
Drug discovery in advanced prostate cancer: translating biology into therapy
Yap, T. A., Smith, A. D., Ferraldeschi, R., Al‐Lazikani, B., Workman, P., & Bono, J. S. D. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.120 · Cited by 157
Managing bone metastases and reducing skeletal related events in prostate cancer
Gartrell, B. A., & Saad, F. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.70 · Cited by 158
Mayrhofer, M., De Laere, B., Whitington, T., Van Oyen, P., Ghysel, C., Ampe, J., Ost, P., Demey, W., Hoekx, L., Schrijvers, D., et al. (2018) · Genome Medicine · doi:10.1186/s13073-018-0595-5 · Cited by 139
Metastatic Prostate Cancer—A Review of Current Treatment Options and Promising New Approaches
Posdzich, P., Darr, C., Hilser, T., Wahl, M., Herrmann, K., Hadaschik, B. A., & Grünwald, V. (2023) · Cancers · doi:10.3390/cancers15020461 · Cited by 156
Management of bone health in solid tumours: From bisphosphonates to a monoclonal antibody
von Moos, R., Costa, L., González‐Suárez, E., Terpos, E., Niepel, D., & Body, J. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.05.003 · Cited by 152
Kiess, A. P., Minn, I., Vaidyanathan, G., Hobbs, R. F., Josefsson, A., Shen, C., Brummet, M., Chen, Y., Choi, J., Koumarianou, E., et al. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.174300 · Cited by 137
Crona, D. J., & Whang, Y. E. (2017) · Cancers · doi:10.3390/cancers9060067 · Cited by 160
“Options for the treatment of mCRPC now include: (1) the autologous cellular immunotherapy, sipuleucel-T, for asymptomatic or minimally symptomatic mCRPC patients (approved by the FDA in 2010) [31]; (2) the semi-synthetic taxane, cabazitaxel, which was shown to be effective in overcoming secondary resistance to docetax…”
BackgroundProduction and Supply of α-Particle–Emitting Radionuclides for Targeted α-Therapy
Radchenko, V., Morgenstern, A., Jalilian, A. R., Ramogida, C. F., Cutler, C. S., Duchemin, C., Hoehr, C., Haddad, F., Bruchertseifer, F., Gausemel, H., et al. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.120.261016 · Cited by 154
“However, (223)Ra in its ionic form is clinically used as Xofigo in the treatment of bone metastatic prostate cancer (18).”
BackgroundGuinney, J., Wang, T., Laajala, T. D., Winner, K. K., Bare, J. C., Neto, E. C., Khan, S. A., Peddinti, G., Airola, A., Pahikkala, T., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30560-5 · Cited by 135
Self-citationCurrent concepts in bone metastasis, contemporary therapeutic strategies and ongoing clinical trials
Gdowski, A., Ranjan, A. P., & Vishwanatha, J. K. (2017) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-017-0578-1 · Cited by 151
Tagawa, S. T., Vallabhajosula, S., Christos, P. J., Jhanwar, Y. S., Batra, J. S., Lam, L., Osborne, J., Beltran, H., Molina, A. M., Goldsmith, S. J., et al. (2019) · Cancer · doi:10.1002/cncr.32072 · Cited by 134
Morris, M. J., Molina, A., Small, E. J., de Bono, J. S., Logothetis, C. J., Fizazi, K., de Souza, P., Kantoff, P. W., Higano, C. S., Li, J., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.3875 · Cited by 133
Barber, T. W., Singh, A., Kulkarni, H. R., Niepsch, K., Billah, B., & Baum, R. P. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.216820 · Cited by 132
“OS with these agents as second-line therapies in selected patient cohorts ranges from 14 to 18 mo (4,8,9,11).”
BackgroundThe treatment landscape of metastatic prostate cancer
Yamada, Y., & Beltran, H. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.06.010 · Cited by 156
Prostate Cancer, Version 1.2014
Mohler, J. L., Kantoff, P. W., Armstrong, A. J., Bahnson, R. R., Cohen, M. B., D'Amico, A. V., Eastham, J. A., Enke, C. A., Farrington, T. A., Higano, C. S., et al. (2013) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2013.0174 · Cited by 141
Sathianathen, N. J., Konety, B. R., Crook, J. M., Fred Saad, C., & Lawrentschuk, N. (2018) · Nature Reviews Urology · doi:10.1038/s41585-018-0060-7 · Cited by 164
Bhatia, V., Kamat, N. V., Pariva, T. E., Wu, L.-T., Tsao, A., Sasaki, K., Sun, H., Javier, G., Nutt, S., Coleman, I., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37874-2 · Cited by 131
Targeting the adaptive molecular landscape of castration‐resistant prostate cancer
Wyatt, A. W., & Gleave, M. E. (2015) · EMBO Molecular Medicine · doi:10.15252/emmm.201303701 · Cited by 127
Ferdinandus, J., Eppard, E., Gaertner, F. C., Kürpig, S., Fimmers, R., Yordanova, A., Hauser, S., Feldmann, G., Essler, M., & Ahmadzadehfar, H. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.178228 · Cited by 139
The role of GATA2 in lethal prostate cancer aggressiveness
Rodríguez-Bravo, V., Carceles‐Cordon, M., Hoshida, Y., Cordon‐Cardo, C., Galsky, M. D., & Domenech, J. M. D. (2016) · Nature Reviews Urology · doi:10.1038/nrurol.2016.225 · Cited by 144
Thompson, M. K., Poortmans, P. M., Chalmers, A. J., Finn, C. F., Hall, E., Huddart, R. A., Lievens, Y. N., Sebag‐Montefiore, D., & Coles, C. E. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0201-z · Cited by 148
Harshman, L. C., Chen, Y., Liu, G., Carducci, M. A., Jarrard, D. F., Dreicer, R., Hahn, N. M., Garcia, J. A., Hussain, M., Shevrin, D. H., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.3921 · Cited by 139
“inhibitors such as abiraterone acetate, bone metastasis–homing radiationwith radium-223, and an autologous dendritic cell vaccine sipuleucel-T.(5-12) Given that these drugs yield only incremental survival benefits, attempts to improve the outcomes of this largely fatal disease have evolved to move these agents forward…”
BackgroundSelf-citationRadium-223 mechanism of action: implications for use in treatment combinations
Morris, M. J., Corey, E., Guise, T. A., Gulley, J. L., Kelly, W. K., Quinn, D. I., Scholz, A., & Sgouros, G. (2019) · Nature Reviews Urology · doi:10.1038/s41585-019-0251-x · Cited by 140
Sternberg, C. N., Bono, J. S. D., Chi, K. N., Fizazi, K. S., Mulders, P., Cerbone, L., Hirmand, M., Forer, D., & Scher, H. I. (2014) · Annals of Oncology · doi:10.1093/annonc/mdt571 · Cited by 132
Hoang, D. T., Iczkowski, K. A., Kilari, D., See, W. A., & Nevalainen, M. T. (2016) · Oncotarget · doi:10.18632/oncotarget.12554 · Cited by 142
Castration-Resistant Prostate Cancer: AUA Guideline Amendment 2018
Lowrance, W. T., Murad, M. H., Oh, W. K., Jarrard, D. F., Resnick, M. J., & Cookson, M. S. (2018) · The Journal of Urology · doi:10.1016/j.juro.2018.07.090 · Cited by 131
Targeting bone metastases in prostate cancer: improving clinical outcome
Body, J., Casimiro, S., & Costa, L. (2015) · Nature Reviews Urology · doi:10.1038/nrurol.2015.90 · Cited by 132
Hammer, S., Hagemann, U. B., Zitzmann-Kolbe, S., Larsen, A., Ellingsen, C., Géraudie, S., Grant, D., Indrevoll, B., Smeets, R., von Ahsen, O., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2268 · Cited by 133
“Thus, the first decay step generates radium-223, which in form of radium-223 dichloride has a welldocumented safety profile and proven survival benefit in prostate cancer patients with bone metastases and no know visceral metastases (5).”
BackgroundInfluentialICRU REPORT 96, Dosimetry-Guided Radiopharmaceutical Therapy
Sgouros, G., Bolch, W. E., Chiti, A., Dewaraja, Y. K., Emfietzoglou, D., Hobbs, R. F., Konijnenberg, M., Gleisner, K. S., Strigari, L., Yen, T., et al. (2021) · Journal of the ICRU · doi:10.1177/14736691211060117 · Cited by 165
Graff, J. N., Beer, T. M., Alumkal, J. J., Slottke, R., Redmond, W. L., THOMAS, G. V., Thompson, R. F., Wood, M. A., Koguchi, Y., Chen, Y., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000642 · Cited by 127
Novel therapies are changing treatment paradigms in metastatic prostate cancer
Powers, E., Karachaliou, G. S., Kao, C., Harrison, M. R., Hoimes, C. J., George, D. J., Armstrong, A. J., & Zhang, T. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00978-z · Cited by 139
Circulating tumour cells—monitoring treatment response in prostate cancer
Miyamoto, D. T., Sequist, L. V. D., & Lee, R. J. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.82 · Cited by 132
Etchebehere, E., Araujo, J. C., Fox, P. S., Swanston, N. M., Macapinlac, H. A., & ROHREN, E. M. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.158626 · Cited by 126
Targeted Alpha-Particle Therapy: A Review of Current Trials
Jang, A., Kendi, A. T., Johnson, G. B., Halfdanarson, T. R., & Sartor, O. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411626 · Cited by 132
“Although beta-emitting isotopes have historically led the way, in 2013, the first alpha emitter was approved (223radium dichloride or 223Ra) after a phase III study (ALSYMPCA) indicated that overall survival could be prolonged with the use of this radionuclide [1].”
BackgroundSelf-citationFizazi, K., & Gillessen, S. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.02.015 · Cited by 119
Tucci, M., Bertaglia, V., Vignani, F., Buttigliero, C., Fiori, C., Porpiglia, F., Scagliotti, G. V., & Maïo, M. D. (2015) · European Urology · doi:10.1016/j.eururo.2015.09.013 · Cited by 131
Endocrine aspects of bone metastases
Hofbauer, L. C., Rachner, T. D., Coleman, R. E., & Jakob, F. J. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70203-1 · Cited by 132
Self-citation
Metadata
- Authors
- Parker, C., Nilsson, S., Heinrich, D., Helle, S. I., O'Sullivan, J. M., Fosså, S. D., Chodacki, A., Wiechno, P., Logue, J., Seke, M., Widmark, A., Johannessen, D. C., Hoskin, P., Bottomley, D., James, N. D., Solberg, A., Syndikus, I., Kliment, J., Wedel, S., Boehmer, S., Dall'Oglio, M., Franzén, L., Coleman, R., Vogelzang, N. J., O'Bryan-Tear, C. G., Staudacher, K., Garcia-Vargas, J., Shan, M., Bruland, Ø. S., & Sartor, O.
- Affiliations
- Institute of Cancer Research (GB)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-07-18
- Volume
- 369
- Issue
- 3
- Pages
- 213-223
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2141454098
- Cited by
- 3,408
- References
- 36
- Citations by year
- 2026: 162 · 2025: 213 · 2024: 230 · 2023: 252 · 2022: 253 · 2021: 307 · 2020: 274 · 2019: 268 · 2018: 321 · 2017: 279 · 2016: 288 · 2015: 253 · 2014: 250 · 2013: 50
- FWCI
- 228.36
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (Queen's University Belfast) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
- Keywords
- radium-223 dichloride, alpha-emitting radiopharmaceuticals, castration-resistant prostate cancer, bone metastasis, overall survival, skeletal-related events, docetaxel, myelosuppression, treatment safety, ALSYMPCA trial, interim analysis
- MeSH terms
- Aged, Aged, 80 and over, Bone Neoplasms, Double-Blind Method, Humans, Isotopes, Male, Middle Aged, Prostatic Neoplasms, Radium, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.